All In Biotech

Drug Trial Radar · NCT00211939

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2)

Last checked: Nov 20, 2026Latest source record: Jan 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 203 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

203

Actual

Start

Jan 2005

Primary completion

Dec 2006

Study completion Mar 2007

Sponsor

Lead sponsor
Nabi BiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron beam computed tomography (CT) scanning, to measure calcium in the coronary arteries, the aortic valve, and the mitral valve.

Conditions

  • Calcinosis
  • Arteriosclerosis
  • Hyperparathyroidism, Secondary

Interventions

  • calcium acetateDrug

    667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level

  • sevelamerDrug

    1-3 tablets t.i.d, titrated to serum phosphorus level

  • atorvastatinDrug

    20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. electron-beam CT coronary artery calcification AGATSTON scoreTime frame: change at 12 mo from baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Texas Health Sciences Center

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.